INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒═══════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                 │ CHIA Criteria                                      │   Score │
╞═══════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Eligible for percutaneous coronary intervention   │ Eligible for percutaneous coronary intervention    │     100 │
│ with Absorb Bioresorbable Vascular Scaffold or    │ with Absorb Bioresorbable Vascular Scaffold or     │         │
│ Everolimus Eluting Stent                          │ Everolimus Eluting Stent                           │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Reference vessel diameter 2.75-4.0                │ Reference vessel diameter 2.75-4.0                 │     100 │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Willing and able to provide informed written      │ Willing and able to provide informed written       │     100 │
│ consent                                           │ consent                                            │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Woman who are breastfeeding, pregnant or planning │ Woman who are breastfeeding, pregnant or planning  │     100 │
│ to become pregnant during the course of the study │ to become pregnant during the course of the study  │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with bifurcation lesions requiring 2     │ Bifurcation lesion requiring 2 stenting technique  │      85 │
│ stenting technique                                │                                                    │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Lesion length ≤ 40mm                              │ Lesion length = 40                                 │      89 │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Plaque burden\>70%                                │ plaque burden>70%                                  │      91 │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with contraindications to or planned     │ Contraindication to or planned discontinuation of  │      91 │
│ discontinuation of dual antiplatelet therapy      │ dual antiplatelet therapy within 1 year            │         │
│ within 1 year                                     │                                                    │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Large lipid-rich plaque on NIRS(Intracoronary     │ Lipid-rich plaque on NIRS(Intracoronary Near-      │      94 │
│ Near-Infrared Spectroscopy), defined as           │ Infrared Spectroscopy) (defined as maxLCBI4mm>315) │         │
│ MaxLCBI4mm\>315                                   │                                                    │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients for whom the preferred treatment is      │ Patients in whom the preferred treatment is        │      97 │
│ CABG(Coronary artery bypass grafting)             │ CABG(Coronary artery bypass grafting)              │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ MLA(minimal luminal area)\<4mm2                   │ MLA(minimal luminal area)<4mm2                     │      98 │
╘═══════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════════════════════╤═══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                 │ CHIA Criteria                                     │   Score │
╞═══════════════════════════════════════════════════╪═══════════════════════════════════════════════════╪═════════╡
│ TCFA(thin-cap fibroatheroma) defined as fibrous   │ Woman who are breastfeeding, pregnant or planning │      33 │
│ cap thickness \<65 μm and arc \>90° on optical    │ to become pregnant during the course of the study │         │
│ coherence tomography (OCT) or ≥10% confluent      │                                                   │         │
│ necrotic core with \>30° abutting the lumen in    │                                                   │         │
│ three consecutive slices on Virtual-histology     │                                                   │         │
│ intravascular ultrasound (VH-IVUS)                │                                                   │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years                 │ The patients who have more than or equal to 3     │      39 │
│                                                   │ target lesions                                    │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Patients with at least one significant stenosis   │ Woman who are breastfeeding, pregnant or planning │      40 │
│ (diameter stenosis \>50%) with Fractional Flow    │ to become pregnant during the course of the study │         │
│ Reserve (FFR) \>0.80 and meeting two of the       │                                                   │         │
│ following criteria                                │                                                   │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Patients with suspected or known Coronary artery  │ Patients in whom the preferred treatment is       │      49 │
│ disease who are undergoing invasive cardiac       │ CABG(Coronary artery bypass grafting)             │         │
│ catheterization                                   │                                                   │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Patients aged ≥18 years                           │ Age 18 years or older                             │      50 │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Patients with stented lesions                     │ Stented lesion                                    │      60 │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Patients with life expectancy \<2 years           │ Life expectancy less than 2 years                 │      61 │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Patients with bypass graft lesions                │ Bypass graft lesion                               │      68 │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Patients with three or more target lesions        │ The patients who have more than or equal to 3     │      69 │
│                                                   │ target lesions                                    │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Patients with planned cardiac or major noncardiac │ Planned cardiac surgery or planned major non      │      74 │
│ surgery                                           │ cardiac surgery                                   │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Patients with heavily calcified or angulated      │ Heavily calcified or angulated lesion             │      81 │
│ lesions                                           │                                                   │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Patients with two target lesions in the same      │ 2 target lesions in the same coronary territory   │      84 │
│ coronary territory                                │                                                   │         │
╘═══════════════════════════════════════════════════╧═══════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒═══════════════════════════════════════════════════╤═════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                 │ CHIA Criteria                                   │   Score │
╞═══════════════════════════════════════════════════╪═════════════════════════════════════════════════╪═════════╡
│ Patients aged ≥18 years                           │ Age 18 years or older                           │      50 │
├───────────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ Patients with stented lesions                     │ 2 target vulnerable lesions                     │      50 │
├───────────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ Patients for whom the preferred treatment is      │ Symptomatic or asymptomatic coronary artery     │      51 │
│ CABG(Coronary artery bypass grafting)             │ disease patients                                │         │
├───────────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ Patients with stented lesions                     │ Stented lesion                                  │      60 │
├───────────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ Patients with life expectancy \<2 years           │ Life expectancy less than 2 years               │      61 │
├───────────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ Patients with bypass graft lesions                │ Bypass graft lesion                             │      68 │
├───────────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ Patients with three or more target lesions        │ The patients who have more than or equal to 3   │      69 │
│                                                   │ target lesions                                  │         │
├───────────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ Patients with planned cardiac or major noncardiac │ Planned cardiac surgery or planned major non    │      74 │
│ surgery                                           │ cardiac surgery                                 │         │
├───────────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ Patients with heavily calcified or angulated      │ Heavily calcified or angulated lesion           │      81 │
│ lesions                                           │                                                 │         │
├───────────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ Patients with two target lesions in the same      │ 2 target lesions in the same coronary territory │      84 │
│ coronary territory                                │                                                 │         │
╘═══════════════════════════════════════════════════╧═════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 69
Average Levenshtein Ratio of individual lines: 72.75757575757575
OverAll Ratio: 70.87878787878788
